Dr. Joseph Pantginis

H.C. Wainwright & Co.

Image: Dr. Joseph Pantginis

Joseph Pantginis, Ph.D., joined H.C. Wainwright as Managing Director covering Biotechnology. Dr. Pantginis has over 15 years of sell-side experience covering biotechnology companies, having spent most of those years at ROTH Capital Partners and Canaccord Adams. Prior to his sell-side career, he worked at Regeneron Pharmaceuticals, where he founded the Retrovirus Core Facility, providing molecular biology service and retroviral vectors to a broad range of Regeneron's research programs. His therapeutic focus is oncology, as well as regenerative medicine and gene therapy. He is also widely recognized for his expertise in cancer immunotherapy as a therapeutic approach to treating cancer. Dr. Pantginis received a B.S. in Biology from Fordham University, an M.B.A. in finance from Pace University, and a Ph.D. in Molecular Genetics from the Albert Einstein College of Medicine.

Recent Articles

Biopharma Acquires Royalty on Approved Diabetes Drug 11/03/2023

This is one of the California-based company's many transactions resulting from its royalty monetization strategy, noted an H.C. Wainwright & Co. report.

Co. Reaches Major Milestone With Novel Drug 09/07/2023

The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor, noted an H.C. Wainwright & Co. report.

Recent Quotes

"It is an opportune time to explore the investment case of ATNM based on the late stage nature of the lead asset, addressing unmet medical needs, clinical data in hand, and a broad set of upcoming catalysts."

— Dr. Joseph Pantginis, ROTH Capital Partners (10/31/16)
more >

Due to permission requirements, not all quotes are shown.